Soluble ST2 levels are not associated with secondary cardiovascular events and vulnerable plaque phenotype in patients with carotid artery stenosis

Atherosclerosis

Volumn 231, Issue 1, 2013, Pages 48-53

  Willems, Sanne ^a   Quax, Paul H A ^b   de Borst, Gert Jan ^a   de Vries, Jean Paul P M ^c   Moll, Frans L ^a   de Kleijn, Dominique P V ^a,d,e   Hoefer, Imo E ^a   Pasterkamp, Gerard ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ST ANTONIUS HOSPITAL   (Netherlands)

^d ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^e NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Atherosclerosis; Biomarker; Carotid; Inflammation; Receptor; ST2

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 2; PROTEIN; PROTEIN ST2; UNCLASSIFIED DRUG;

AGED; ARTICLE; CAPILLARY DENSITY; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ATHEROSCLEROSIS; BIOMARKER; CAROTID; INFLAMMATION; RECEPTOR; ST2;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CAROTID ARTERY DISEASES; CAROTID STENOSIS; ENDARTERECTOMY, CAROTID; FOLLOW-UP STUDIES; HUMANS; PLAQUE, ATHEROSCLEROTIC; PROGNOSIS; RECEPTORS, CELL SURFACE; SOLUBILITY;

EID: 84885391431     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.08.024     Document Type: Article

References (35)

1. Bergers G., Reikerstorfer A., Braselmann S., Graninger P., Busslinger M. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J 1994, 13:1176-1188.
2. Weinberg E.O., Shimpo M., Hurwitz S., et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003, 107:721-726.
3. Bartunek J., Delrue L., Van Durme F., et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. JAm Coll Cardiol 2008, 52:2166-2174.
4. Miller A.M., Liew F.Y. The IL-33/ST2 pathway-a new therapeutic target in cardiovascular disease. Pharmacol Ther 2011, 131:179-186.
5. Schmitz J., Owyang A., Oldham E., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23:479-490.
6. Sanada S., Hakuno D., Higgins L., et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. JClin Invest 2007, 117:1538-1549.
7. Seki K., Sanada S., Kudinova A.Y., et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail 2009, 2:684-691.
8. Turnquist H.R., Zhao Z., Rosborough B.R., et al. IL-33 expands suppressive CD11b+ Gr-1int and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. JImmunol 2011, 187:4598-4610.
9. Miller A.M., Xu D., Asquith D.L., et al. IL-33 reduces the development of atherosclerosis. JExp Med 2008, 205:339-346.
10. Hayakawa H., Hayakawa M., Kume A., Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. JBiol Chem 2007, 282:26369-26380.
11. Willems S., Hoefer I., Pasterkamp G. The role of the interleukin 1 receptor-like 1 (ST2) and Interleukin-33 pathway in cardiovascular disease and cardiovascular risk assessment. Minerva Med 2012, 103:513-524.
12. McLaren J.E., Michael D.R., Salter R.C., et al. IL-33 reduces macrophage foam cell formation. JImmunol 2010, 185:1222-1229.
13. Verhoeven B.A.N., Velema E., Schoneveld A.H., et al. Athero-express: differential atherosclerotic plaque expression of mRNA and protein in relation to cardiovascular events and patient characteristics. Rationale and design. Eur J Epidemiol 2004, 19:1127-1133.
14. Endarterectomy for asymptomatic carotid artery stenosis. Executive committee for the asymptomatic carotid atherosclerosis study. JAMA 1995, 273:1421-1428.
15. Rothwell P., Eliasziw M., Gutnikov S., et al. Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet 2003, 361:107-116.
16. Halliday A., Mansfield A., Marro J., et al. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms. Randomised controlled trial. Lancet 2004, 363:1491-1502.
17. Van Lammeren G.W., Moll F.L., Blankestijn P.J., et al. Decreased kidney function: an unrecognized and often untreated risk factor for secondary cardiovascular events after carotid surgery. Stroke 2012, 42:307-312.
18. Hellings W.E., Peeters W., Moll F.L., et al. Composition of carotid atherosclerotic plaque is associated with cardiovascular outcome: a prognostic study. Circulation 2010, 121:1941-1950.
19. Derksen W.J.M., Peeters W., Van Lammeren G.W., et al. Different stages of intraplaque hemorrhage are associated with different plaque phenotypes: a large histopathological study in 794 carotid and 276 femoral endarterectomy specimens. Atherosclerosis 2011, 218:369-377.
20. Weinberg E.O., Schimpo M., De Keulenaer G.W., et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002, 106:2961-2966.
21. Szerafin T., Niederpold T., Mangold A., et al. Secretion of soluble ST2-possible explanation for systemic immunosuppression after heart surgery. Thorac Cardiovasc Surg 2009, 57:25-29.
22. Willems S., Sels J.W., Flier S., et al. Temporal changes of soluble ST2 after cardiovascular interventions. Eur J Clin Invest 2012, 43:113-120.
23. Mueller T., Dieplinger B., Gegenhuber A., et al. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 2008, 54:752-756.
24. Rehman S.U., Mueller T., Januzzi J.L. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. JAm Coll Cardiol 2008, 52:1458-1465.
25. Daniels L.B., Clopton P., Iqbal N., Tran K., Maisel A.S. Association of ST2 levels with cardiac structure and function and mortality in outpatients. Am Heart J 2010, 160:721-728.
26. Pascual-Figal D.A., Manzano-Fernández S., Boronat M., et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail 2011, 13:718-725.
27. Dhillon O.S., Narayan H.K., Khan S.Q., et al. Pre-discharge risk stratification in unselected STEMI: is there a role for ST2 or its natural ligand IL-33 when compared with contemporary risk markers?. Int J Cardiol 2012, 10.1016/j.ijcard.2012.05.073.
28. Wang T.J., Wollert K.C., Larson M.G., et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham heart study. Circulation 2012, 126:1596-1604.
29. Shimpo M., Morrow D.A., Weinberg E.O., et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004, 109:2186-2190.
30. Broch K., Ueland T., Nymo S.H., et al. Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. Eur J Heart Fail 2012, 14:268-277.
31. Fousteris E., Melidonis A., Panoutsopoulos G., et al. Toll/interleukin-1 receptor member ST2 exhibits higher soluble levels in type 2 diabetes, especially when accompanied with left ventricular diastolic dysfunction. Cardiovasc Diabetol 2011, 10:101.
32. Kohli P., Bonaca M.P., Kakkar R., et al. Role of ST2 in Non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem 2012, 58:257-266.
33. Santhanakrishnan R., Chong J.P., Ng T.P., et al. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail 2012, 14:1338-1347.
34. Bao Y.S., Na S.P., Zhang P., et al. Characterization of interleukin-33 and soluble ST2 in serum and their association with disease severity in patients with chronic kidney disease. JClin Immunol 2012, 32:587-594.
35. Miller A.M. Role of IL-33 in inflammation and disease. JInflamm (Lond) 2011, 8:22.